WHO grants emergency approval to 2nd Chinese COVID vaccine AstraZeneca Geneva India Covid Moderna
The World Health Organization has released an emergency use list for the COVID-19 vaccine made by Sinovac for adults 18 and older, the second such clearance it has granted to a Chinese company.
In a statement on Tuesday, the United Nations health agency said data submitted to its experts showed that two doses of the vaccine were preventing people from showing symptoms of COVID-19 in about half of those who received the vaccine. vaccine. The WHO said few older adults were enrolled in the research, so it couldn’t estimate the vaccine’s effectiveness in people over 60.
“Nonetheless, the WHO does not recommend an upper age limit for the vaccine,” the agency said, adding that data collected on the use of Sinovac in other countries “suggests that the vaccine is likely to ‘have a protective effect in the elderly. “
In April, a study published by a team of scientists in Brazil confirmed a previously reported efficacy rate of over 50% for Sinovac. A real-world study in Chile in April found an effectiveness rate of 67%.
Last month, the WHO gave the green light to the COVID-19 vaccine made by Sinopharm. It has also licensed vaccines developed by Pfizer-BioNTech, AstraZeneca Moderna and Johnson & Johnson.
WHO authorization means the vaccine can be purchased by donors and other UN agencies for use in poorer countries, including as part of the UN-backed initiative to distribute COVID-19 vaccines known worldwide as COVAX. The effort was significantly slowed down after its largest supplier in India said it would no longer be able to deliver other vaccines until the end of the year due to the latest wave of new infections now ravaging India.
To date, there is no confirmed agreement for the doses of Sinovac with COVAX.
In May, the European medicines regulator began a fast-track review process for the Sinovac vaccine, but it is unclear when a decision could be made on its possible clearance for the 27-nation bloc.
Hundreds of millions of Chinese vaccines have already been delivered to dozens of countries around the world under bilateral deals, as many countries scrambled to stock up after rich countries reserved the vast majority. supplies to Western pharmaceutical manufacturers.
While China uses five vaccines, the majority of its overseas exports come from two companies: Sinopharm and Sinovac. Chinese vaccines are “inactivated” vaccines, made with a killed coronavirus.
Most of the other COVID-19 vaccines in use around the world, especially in the West, are made with newer technologies that instead target the “spike” protein that covers the surface of the coronavirus.
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine